Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...
Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho ...
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy. On November 24, Truist’s ...
News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...
HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the HIV ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the ...
Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...
Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn’t know her parents suffered HIV-related complications ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback